The Hengrui Pharma drug targets the same receptors as Eli Lilly's blockbuster product tirzepatide ...

But the drug's results appear to be promising, and position it as a potential competitor to Eli Lilly's weekly weight loss injection Zepbound.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, it's from China.

Eli Lilly came out of the ADA conference as a clear winner with impressive datasets of two new mechanisms for obesity – the anti-myostatin antibody bimagrumab and the amylin analog eloralintide.

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial.